Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the first large randomized trial (NCT02775903) of azacitidine with or without immune checkpoint blockade in older unfit acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). While the study did not reach its primary endpoint, Dr Zeidan reveals the important insights that can be taken away. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.